Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 153

Sort by

Sort Order Select

Journal Articles

Patterns of Disease Progression in Patients with Systemic Mastocytosis: A US Population-Level Analysis Using Health Claims-Based Dataset

Sudipto Mukherjee, Doug Cattie, Naveen Pemmaraju, Teresa Green, Dan Shaheen

Blood (2022) 140 (Supplement 1): 6865–6867.

https://doi.org/10.1182/blood-2022-169269

Published: 2022

Journal Articles

Real-World Usage of Asciminib in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the United States (US) Using a Large Claims Database

Sudipto Mukherjee, Chi-Chang Chen, Magdaliz Gorritz, Islam Sadek, Serban Iorga, Zifan Zhou, Jing He, Rodrigo Maegawa, Andrea Damon, Germano Ferreira, Kejal Jadhav

Blood (2022) 140 (Supplement 1): 13297–13298.

https://doi.org/10.1182/blood-2022-166473

Published: 2022

Journal Articles

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Elias Jabbour, Paul B. Koller, Vivian G. Oehler, Omer H Jamy, Sudipto Mukherjee, Anthony M. Hunter, Maria R. Baer, Joseph T. Beck, Zi Chen, Huanshan Guo, Lei Fu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Hagop Kantarjian, Lixin Jiang, Cunlin Wang

Blood (2022) 140 (Supplement 1): 200–202.

https://doi.org/10.1182/blood-2022-162387

Published: 2022

Journal Articles

Clinical and Molecular Features of FTL3 non Canonical and Activation Loop Mutations

Jaymeson Gordon, Christopher Haddad, Ishani Nautiyal, Yasuo Kubota, Hetty E. Carraway, Sudipto Mukherjee, Aaron T. Gerds, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Carmelo Gurnari, Valeria Visconte

Blood (2022) 140 (Supplement 1): 9152–9154.

https://doi.org/10.1182/blood-2022-170094

Published: 2022

Journal Articles

ANKRD26 Coding Variants in Myeloid Neoplasia

Teodora Kuzmanovic, Metis Hasipek, Samuel Li, Thomas Laframboise, Valeria Visconte, Sunisa Kongkiatkamon, Seth J. Corey, Sudipto Mukherjee, Anjali Advani, Aaron T. Gerds, Yogenthiran Saunthararajah, Sophia R. Balderman, Abhay Singh Singh, Hetty E. Carraway, Niroshan Nadarajah, Manja Meggendorfer, Jaroslaw P. Maciejewski, Bhumika J. Patel

Blood (2022) 140 (Supplement 1): 4013–4015.

https://doi.org/10.1182/blood-2022-170645

Published: 2022

Journal Articles

Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry

Julia H. Joo, Yanwen Chen, Aaron T. Gerds, Anjali Advani, Sophia R. Balderman, Hetty E. Carraway, Abhay Singh Singh, Sudipto Mukherjee

Blood (2022) 140 (Supplement 1): 687–689.

https://doi.org/10.1182/blood-2022-163565

Published: 2022

Journal Articles

Exploratory Validation of a Bespoke International Patient Symptom Survey in Idiopathic Multicentric Castleman's Disease Using Psychometric Testing: Implications for Clinical Practice and Routine Data Collection

Sudipto Mukherjee, Matthew Franklin, Francis Shupo, Nicola Mason, Grace Wayi-Wayi, Natasa Zibelnik, Mileva Repasky, John Brazier

Blood (2022) 140 (Supplement 1): 10885–10886.

https://doi.org/10.1182/blood-2022-168744

Published: 2022

Journal Articles

A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia

Blood (2022) 140 (Supplement 1): 2075–2077.

https://doi.org/10.1182/blood-2022-162913

Published: 2022

Journal Articles

Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns

Sudipto Mukherjee, Cherrishe Brown-Bickerstaff, Ali McBride, Ajeet Gajra, Danielle Gentile, Angelica Falkenstein, Talia Miller, JaLyna Laney, Kristin M. Savill, Adeola Y. Makinde

Blood (2022) 140 (Supplement 1): 944–946.

https://doi.org/10.1182/blood-2022-156902

Published: 2022

Journal Articles

Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US

Sudipto Mukherjee, Kristin M. Savill, Ajeet Gajra, Danielle Gentile, Angelica Falkenstein, Talia Miller, JaLyna Laney, Ali McBride

Blood (2022) 140 (Supplement 1): 10998–11000.

https://doi.org/10.1182/blood-2022-156892

Published: 2022

Journal Articles

Co-Occurrence of MDS with MGUS Represents a Unique Disease Entity with Specific Molecular Phenotype and Potential Improved Clinical Outcome

Tariq Kewan, Ramsha Ahmed, Carmelo Gurnari, Waled Bahaj, Simona Pagliuca, Yogenthiran Saunthararajah, Bhumika J. Patel, Sudipto Mukherjee, Aaron T. Gerds, Anjali Advani, Valeria Visconte, Jaroslaw P. Maciejewski, Hetty E. Carraway

Blood (2021) 138 (Supplement 1): 1529.

https://doi.org/10.1182/blood-2021-151858

Published: 2021

Journal Articles

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Blood (2021) 138 (Supplement 1): 3436.

https://doi.org/10.1182/blood-2021-150277

Published: 2021

Journal Articles

Molecular Derivation of Extramedullary Myeloid Sarcomas Based on Machine Learning Analysis of Genomic Clusters in AML

Tariq Kewan, Carmelo Gurnari, Waled Bahaj, Simona Pagliuca, Hassan Awada, Suresh Kumar Balasubramanian, Bhumika J. Patel, Sudipto Mukherjee, Anjali Advani, Valeria Visconte, Hetty E. Carraway, James R. Cook, Heesun J. Rogers, Jaroslaw P. Maciejewski

Blood (2021) 138 (Supplement 1): 1295.

https://doi.org/10.1182/blood-2021-151803

Published: 2021

Journal Articles

Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States

Kristin M. Zimmerman Savill, Ajeet Gajra, Kwanza Price, Jonathan K. Kish, Cherrishe Brown-Bickerstaff, Angelica Falkenstein, Talia Miller, JaLyna Laney, Sudipto Mukherjee

Blood (2021) 138 (Supplement 1): 4657.

https://doi.org/10.1182/blood-2021-146461

Published: 2021

Journal Articles

Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)

Elias J. Jabbour, Hagop Kantarjian, Ghayas C. Issa, Joseph Thaddeus Beck, Rebecca B. Klisovic, Sudipto Mukherjee, Vivian G. Oehler, Zi Chen, Ming Lu, Tommy Fu, Lixin Jiang, Yifan Zhai, Dajun Yang

Blood (2021) 138 (Supplement 1): 2551.

https://doi.org/10.1182/blood-2021-152693

Published: 2021

Journal Articles

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Blood (2021) 138 (5): 387–400.

https://doi.org/10.1182/blood.2020008812

Published: 2021

Includes: Supplemental data

Journal Articles

A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-139412

Published: 2020

Journal Articles

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Nathan Radakovich, BA, David A. Sallman, MD, Rena J. Buckstein, MD FRCPC, Andrew M. Brunner, MD, Sudipto Mukherjee, MD PhD MPH, Rami Komrokji, MD, Najla Al Ali, M.Sc, Jacob Shreve, MD MS, Yazan Rouphail, Cassandra M Kerr, MS, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-139815

Published: 2020

Journal Articles

A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients

Sudipto Mukherjee, MD PhD MPH, Rabecka Martin, PhD, Brenda Sande, Chad Glen, PhD, Jeremy Paige, MDPhD, Suresh Yarlagadda, MD MPH, David C Fajgenbaum, MDMBA,MSc

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-140449

Published: 2020

Journal Articles

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Anjali S Advani, MD, Madeline Waldron, PharmD, BCOP, Caitlin Siebenaller, PharmD, Jenna Thomas, Eric Parsons, RN, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MDMS, Bhumika J. Patel, MD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139515

Published: 2020

NARROW

Patterns of Disease Progression in Patients with Systemic Mastocytosis: A US Population-Level Analysis Using Health Claims-Based Dataset

Real-World Usage of Asciminib in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the United States (US) Using a Large Claims Database

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Clinical and Molecular Features of FTL3 non Canonical and Activation Loop Mutations

ANKRD26 Coding Variants in Myeloid Neoplasia

Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry

Exploratory Validation of a Bespoke International Patient Symptom Survey in Idiopathic Multicentric Castleman's Disease Using Psychometric Testing: Implications for Clinical Practice and Routine Data Collection

A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia

Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns

Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US

Co-Occurrence of MDS with MGUS Represents a Unique Disease Entity with Specific Molecular Phenotype and Potential Improved Clinical Outcome

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Molecular Derivation of Extramedullary Myeloid Sarcomas Based on Machine Learning Analysis of Genomic Clusters in AML

Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States

Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

A Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only